v3.26.1
Revenues from Contracts and Significant Customers (Tables)
12 Months Ended
Dec. 31, 2025
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Year Ended December 31, 

($ in thousands)

  ​ ​ ​

2025

  ​ ​ ​

2024

Emrosi

$

14,745

$

Qbrexza

25,014

25,114

Accutane

12,882

19,407

Foam franchise products (Amzeeq & Zilxi)

5,859

6,652

Other / legacy product revenue

2,739

3,961

Collaboration revenue

1,500

Revenue – related party

 

 

41

Other revenue

2,023

 

1,000

Total net revenue

$

63,262

$

57,675